[1. DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s cancer: Principles & practice of oncology. 10th ed., 2014, United States: Lippincott Williams and Wilkins, 1540.]Search in Google Scholar
[2. Mentzel T, van den Berg E, Molenaar W. Myxofibrosarcoma. In: Fletcher C, Unni K, Mertens F. WHO classification of tumors - pathology and genetics, tumors of soft tissue and bone. 2002, Lyon: IARC Press, 102-1031.]Search in Google Scholar
[3. Castro BAC, Piancastelli ACC, Meyer RLB, Piancastelli PM, Ribeiro CA, Miranda RMC. Myxofibrosarcoma - Case report. 2016; 91(1):97-9.10.1590/abd1806-4841.20163922]Search in Google Scholar
[4. Dodd LG, Bui MM. Atlas of Soft Tissue and Bone Pathology: With Histologic, Cytologic, and Radiologic Correlations. 2015, New York: Demos Medical, 68-71.]Search in Google Scholar
[5. Schepper AM, Vanhoenacker F, Gielen J, Parizel PM. Imaging of soft tissue tumors. 3. 2006, Berlin Heidelberg New York: Springer-Verlag, 196-198.10.1007/3-540-30792-3]Search in Google Scholar
[6. Mentzel T, Calonje E, Wadden C, Camplejohn RS, Beham A, Smith MA, Fletcher CD. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J SurgPathol. 1996; 20:391-405.10.1097/00000478-199604000-00001]Search in Google Scholar
[7. Merck C, Angervall L, Kindblom LG, Oden A. Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastichistiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta PatholMicrobiol Immunol Scand. 1953; Suppl 282:1-40.]Search in Google Scholar
[8. Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977; 39:1672-1685.10.1002/1097-0142(197704)39:4<1672::AID-CNCR2820390442>3.0.CO;2-C]Search in Google Scholar
[9. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997; 350:1647–54.10.1016/S0140-6736(97)08165-8]Search in Google Scholar
[10. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. ClinOrthopRelat Res. 1980; 153:106-120.10.1097/00003086-198011000-00013]Search in Google Scholar
[11. Smolle MA, Dimosthenis A, Per-Ulf T, Szkandera J, Liegl-Atzwanger B, Leithner A. Diagnosis and treatment of soft-tissue sarcomas of the extremities and trunk. EFORT Open Rev. 2017; 2:421-431.10.1302/2058-5241.2.170005]Search in Google Scholar
[12. The ESMO/ European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2014; 25:iii102-iii112.10.1093/annonc/mdu254]Search in Google Scholar
[13. Judson I, Verweij J, Gelderblom H et al. European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupDoxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014; 15:415-423.10.1016/S1470-2045(14)70063-4]Open DOISearch in Google Scholar
[14. Antman K, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J ClinOncol. 1993; 11:1276-1285.10.1200/JCO.1993.11.7.1276]Search in Google Scholar